Eyeforpharma Barcelona 2020 is now a free virtual event

pharmafile | March 25, 2020 | News story | Medical Communications, Research and Development COVID-19, Eyeforpharma Barcelona 2020, coronavirus, events, eyeforpharma, pharma 

In light of the rapidly evolving impact of the COVID-19 virus, eyeforpharma has decided to turn eyeforpharma Barcelona 2020 into a completely virtual event.

To safeguard the health of participants, the physical event will not go ahead. However, to meet increased and sustained demand for idea-sharing and inspiration, however between 31 March and 3 April, more than 2,000 attendees will be able to experience the first online edition of this event.

“Despite our travel restrictions, there has never been a greater need for us to work together, share ideas and fulfil our industry’s potential. For that reason, we must deliver what value we can: our industry’s future depends on such learning and connecting. We are proud to be launching a virtual offering that includes all the event content, education, networking and more,” said Blair Gottscho, Managing Director of eyeforpharma.

She continued: “The decision was made after talking to participants and with the wellbeing of customers and staff. We would like to particularly thank our speakers and panellists who, despite the disruption, have pledged their support to present virtually and ensure our industry continues to thrive through a very turbulent period.” 

Current attendees, speakers and sponsors are automatically signed-up to the virtual event. Those not yet registered who wish to sign up can do by requesting information here. 

More information can be found here:

Related Content

ACM Biolabs shares positive results from phase 1 SARS-CoV-2 booster vaccine trial

ACM Biolabs has announced positive topline results from its phase 1 trial of ACM-001, an …

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo

On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …

Latest content